<DOC>
	<DOCNO>NCT02677519</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability methylphenidate hydrochloride extended-release capsule ( Aptensio XR速 ) child age 4-5 year diagnose attention-deficit/hyperactivity disorder ( ADHD ) . Safety tolerability evaluate assess treatment-emergent adverse event ( TEAEs ) blood pressure , pulse , height , weight , electrocardiogram ( ECGs ) , laboratory The primary objective study evaluate long-term ( 12-month ) safety tolerability Aptensio XR速 child age 4 less 6 year diagnose ADHD . Safety tolerability evaluate assess treatment-emergent adverse event ( TEAEs ) blood pressure , pulse , height , weight , electrocardiogram ( ECGs ) , laboratory value Columbia Suicide Severity Rating Scale ( C-SSRS ) . Disturbances sleep ( quantity quality ) pattern also assess use Child Sleep Habits Questionnaire ( CSHQ ) . Secondary objective include assessment long-term efficacy Aptensio XR速 . Secondary measure include : - Investigator administer Attention-Deficit/Hyperactivity Disorder Rating Scale Preschool Version ( ADHD-RS-IV Preschool Version ) - Clinical Global Impressions-Severity Scale ( CGI-S ) - Connors Early Childhood Behavior-Parent Short form [ Conners EC BEH-P ( S ) ]</brief_summary>
	<brief_title>A 12-Month Open Label Safety Study Aptensio XR速 Children Ages 4-5 Years Diagnosed With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Male female subject age 4 less 6 year inclusive time consent give participate Prior Studies . New Subjects must least 4 year less 6 year age write consent give participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>child</keyword>
	<keyword>methylphenidate</keyword>
</DOC>